# 5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females

> **NCT02356107** · PHASE4 · COMPLETED · sponsor: **Perry Renshaw** · enrollment: 15 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** 5-hydroxytryptophan and Creatine monohydrate

## Key facts

- **NCT ID:** NCT02356107
- **Lead sponsor:** Perry Renshaw
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2018-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02356107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02356107, "5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02356107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*